Moderna (MRNA) Cash from Investing Activities (2018 - 2026)

Moderna (MRNA) has 9 years of Cash from Investing Activities data on file, last reported at -$76.0 million in Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at -$76.0 million, down 110.41% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 billion (down 55.49% YoY), and the FY2025 annual result was $1.9 billion, changed 0.15% from the prior year.
• Cash from Investing Activities retreated to -$76.0 million in Q1 2026 per MRNA's latest filing, from -$48.0 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $2.0 billion in Q1 2023 and troughed at -$3.9 billion in Q1 2022.
• A 5-year average of $167.6 million and a median of $564.0 million in 2025 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2022 and 2025: Cash from Investing Activities tumbled 2078.33% in 2022, then surged 518.64% in 2025.
• A 5-year view of Cash from Investing Activities shows it stood at -$1.0 billion in 2022, then surged by 48.66% to -$538.0 million in 2023, then dropped by 0.19% to -$539.0 million in 2024, then soared by 91.09% to -$48.0 million in 2025, then slumped by 58.33% to -$76.0 million in 2026.
• Business Quant data shows MRNA's Cash from Investing Activities at -$76.0 million in Q1 2026, -$48.0 million in Q4 2025, and $700.0 million in Q3 2025.